Developing GI-restricted biologic medicines
Plantibodies is building a pipeline of orally delivered biologics designed to act locally in the gastrointestinal tract.
Our product-led strategy combines focused proprietary therapeutic development with industry-funded programs that extend the technology across biologic modalities and gastrointestinal diseases.
THERAPEUTIC FOCUS
We focus on diseases where biologic activity within the gastrointestinal tract could provide a differentiated therapeutic approach. Our programs span three areas: immunology and inflammation, rare gastrointestinal diseases, and GI oncology.
Immunology & Inflammation
Inflammatory bowel disease is the primary therapeutic focus of Plantibodies' proprietary pipeline.
Biologic therapies have transformed the treatment of ulcerative colitis and Crohn's disease by targeting key pathways involved in intestinal inflammation. However, these therapies are generally administered systemically, resulting in whole-body exposure to drugs whose therapeutic activity is ultimately required within the gastrointestinal tract.
Plantibodies is exploring a different therapeutic approach: delivering biologics orally and directly to the colon, with the objective of generating high local exposure and pharmacological activity at the site of disease while limiting systemic exposure.
This exposure profile could enable differentiated therapeutic strategies for selected IBD targets and biologics, including molecules already validated through systemic administration as well as emerging mechanisms where local intervention is scientifically compelling.
Rare GI Diseases
Plantibodies is working with industry partners to explore the application of its oral delivery technology in rare gastrointestinal diseases.
These collaborations apply the Plantibodies technology to selected biologics and generate additional preclinical evidence across distinct disease settings.
Individual programs and therapeutic candidates remain confidential.
GI Oncology
Gastrointestinal oncology has provided an important setting to evaluate the ability of the Plantibodies technology to deliver a conventional full-length monoclonal antibody orally and generate local pharmacological activity.
Using an immune checkpoint antibody as a model biologic, Plantibodies has demonstrated oral delivery to the colon, local target engagement and downstream immune activation in vivo.
These studies provide preclinical evidence that a functional full-length antibody can be delivered orally to the colon and remain pharmacologically active following gastrointestinal transit.
This work provides an important foundation for the broader development of GI-restricted antibody therapeutics.
OUR STRATEGY
A product-led platform: Plantibodies combines focused proprietary drug development with industry partnerships to build value at both the therapeutic product and technology levels.
Proprietary programs: Building therapeutic assets
We select opportunities where local GI delivery could create a differentiated therapeutic profile and advance them toward product-level proof of concept.
Partnered programs: Expanding through collaboration
We work with pharmaceutical and biotechnology partners on selected biologics and disease opportunities, generating additional evidence while extending the application of the technology.